Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Hughes, Richard A C ^a   Pritchard, Jane ^b   Hadden, Robert D M ^c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CHINESE DRUG; CORTICOSTEROID; IMMUNOGLOBULIN; TRIPTERYGIUM POLYGLYCOSIDE; UNCLASSIFIED DRUG; BETA INTERFERON; PLANT MEDICINAL PRODUCT;

CEREBROSPINAL FLUID FILTRATION; CLINICAL OUTCOME; DISABILITY; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; GUILLAIN BARRE SYNDROME; HUMAN; INTERMETHOD COMPARISON; MEDICAL PROCEDURES; PLASMA EXCHANGE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; WALKING; CEREBROSPINAL FLUID; FILTRATION; META ANALYSIS; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIPTERYGIUM;

ADRENAL CORTEX HORMONES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBROSPINAL FLUID; FILTRATION; GUILLAIN-BARRE SYNDROME; HUMANS; INTERFERON-BETA; PLANT PREPARATIONS; PLASMA EXCHANGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIPTERYGIUM;

EID: 84875489316     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008630.pub3     Document Type: Review

References (77)

1. Bensa S, Hadden RD, Hahn A, Hughes RA, Willison HJ. Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study. European Journal of Neurology 2000;7(4):423-6. [PUBMED: 10971602]
2. Pritchard J, Gray IA, Hughes RAC, Idrissova ZR, Lecky BRF, Swan AV, et al.A pilot randomised, double-blind, placebo-controlled exploratory safety study of the use of interferon-beta 1a in the treatment of Guillain-Barré syndrome. Journal of the Peripheral Nervous System 2003;8(Suppl 1):52.
3. Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV, et al.A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology 2003;61(9):1282-4. [PUBMED: 14610140]
4. Wollinsky KH, Hülser PJ, Brinkmeier H, Aulkemeyer P, Bössenecker W, Huber-Hartmann KH, et al.CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology 2001;57(5):774-80. [PUBMED: 11552002]
5. Zhang X, Xia J, Ye H. Effect of Tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barre syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban 2000;20(5):332-4. [PUBMED: 11789240]
6. Ahuja GK, Mohandas S, Virani V. Cyclophosphamide in Landry-Guillain-Barré syndrome. Acta Neurologica 1980;2(3):186-90. [PUBMED: 7415884]
7. Bos Eyssen ME, van Doorn PA, Jacobs BC, Steyerberg EW, van der Voort PH, Zandstra DF, et al.Selective digestive tract decontamination decreases time on ventilator in Guillain-Barre syndrome. Neurocritical Care 2011;15(1):128-33.
8. Colin-Jones DG, Heathfield KWG. 6-mercaptopurine in polyradiculoneuropathy. Lancet 1965;2:739.
9. Créange A, Lerat H, Meyrignac C, Degos JD, Gherardi R, Cesaro P. Treatment of Guillain-Barré syndrome with interferon-beta. Lancet 1998;352(9125):368-9.
10. De Grandis D, Santoro L, Di Benedetto P. L-acetylcarnitine in the treatment of patients with peripheral neuropathies: a short term, double-blind clinical study of 426 patients. Clinical Drug Investigation 1995;10(6):317-22.
11. Feasby TE. Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies. Journal of Neurology, Neurosurgery & Psychiatry 1991;54(1):51-4. [PUBMED: 1901348]
12. Francesconi G, Mellina S. Clinical trial of a new coenzymatic complex (Ro 8-0743-4). [Italian]. Clinica Terapeutica 1972;62(3):253-71. [PUBMED: 4507658]
13. Gamstorp I, Aronsson S, Lindquist B. Mercaptopurine in polyradiculoneuropathy. Lancet 1966;i:99-100.
14. Garssen MP, van Koningsveld R, van Doorn PA, Merkies IS, Scheltens-de BM, van Leusden JA, et al.Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study. Journal of Neurology, Neurosurgery & Psychiatry 2007;78(9):1012-3. [PUBMED: 17702789]
15. Garssen MPJ, van Koningsveld R, van Doorn PA. Treatment of Guillain-Barré syndrome with intravenous immunoglobulins and methylprednisolone combined with mycophenolate (CELLCEPT®) - a pilot study. Journal of the Peripheral Nervous System 2005;10:S24.
16. Gorbunov FE, Vinnikov AA, Strelkova NI, Krupennikov AI. The use of pulsed and continuous UHF electrical fields in the rehabilitation of patients with the Guillain-Barre syndrome and other peripheral myelinopathies. [Russian]. Zhurnal Nevrologii i Psikhiatrii Imeni S S Korsakova 1995;95(5):22-6.
17. Hammond JM, Potgieter PD. Neurologic disease requiring long-term ventilation. The role of selective decontamination of the digestive tract in preventing nosocomial infection. Chest 1993;104(2):547-51.
18. Hilz MJ, Claus D, Druschky KF, Rechlin T. Air fluidization therapy of pressure sores due to Guillain-Barre and Cushing syndrome. Intensive Care Medicine 1992;18(1):62-3.
19. Huang LG, Wei XB. Ultraviolet rays for Guillain-Barre syndrome. Chinese Journal of Physical Therapy 1998;21:119-20.
20. Huang XM, Yuan GG. Ultraviolet radiation and oxygen enrichment self-blood transfusion therapy for Guillain-Barre syndrome. Chinese Journal of Neurology 1998;31:123.
21. Husstedt IW, Thumler R, Roder R, Dreyer M, Leopold W, Scheller W. Treatment of polyneuropathies. Investigations on efficacy of ginkgo biloba extract EGb 761 in patients with polyneuropathy. [German]. Zeitschrift fur Allgemeinmedizin 1993;69(26):714-17.
22. Li AY, Wang HX, Liu QX, Sun JX, Lu SJ, Yang Z. Ultraviolet rays for Guillain-Barré syndrome. Chinese Journal of Physical Therapy 1998;21:178-9.
23. Meythaler JM, Guin RS, Johnson A, Brunner RM. The safety and efficacy of 4-aminopyridine for motor weakness due to Guillain-Barré syndrome: a double-blind cross-over phase I drug trial. Archives of Physical Medicine & Rehabilitation 2000;81:1293.
24. Ostronoff F, Perales MA, Stubblefield MD, Hsu KC, Ostronoff F, Perales MA, et al.Rituximab-responsive Guillain-Barre syndrome following allogeneic hematopoietic SCT. Bone Marrow Transplantation 2008;42(1):71-2.
25. Palmer KNV. Polyradiculoneuropathy (Guillain-Barré syndrome) treated with 6-mercaptopurine. Lancet 1965;1(7388):733-4.
26. Palmer KNV. Polyneuropathy treated with cytotoxic drugs. Lancet 1966;1:265.
27. Rosen AD, Vastola EF. Clinical effects of cyclophosphamide in Guillain-Barre polyneuritis. Journal of the Neurological Sciences 1976;30(1):179-87. [PUBMED: 978223]
28. Schaller B, Radziwill AJ, Steck AJ. Successful treatment of Guillain-Barré syndrome with combined administration of interferon-beta-1a and intravenous immunoglobulin. European Neurology 2001;46(3):167-8. [PUBMED: 11598343]
29. Wang H, Li M, Wang F, Dong G, Wang J, Zhang E. Electroacupuncture at shu-points of the five zang-organs for treatment of the flaccidity syndrome. Chinese Journal of Clinical Rehabilitation 2006;10(3):124-6.
30. Warembourg H, Jaillard J. Clinical trial of "F.E.V. 300". Apropos of 300 cases. [French]. Lille Medical 1967;12(7 (Suppl)):746-8. [PUBMED: 5615429]
31. Yuill GM, Swinburn WR, Liversedge LA. Treatment of polyneuropathy with azathioprine. Lancet 1970;2(7678):854-6. [PUBMED: 4097759]
32. Zagar M. Treatment of Guillain-Barré syndrome. Lijecnicki Vjesnik 1995;117(9-10):246-9. [PUBMED: 8643618]
33. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Annals of Neurology 1990;27(Suppl):S21-4. [PUBMED: 2194422]
34. Bernsen RA, de Jager AE, Schmitz PI, van der Meché FG. Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome. Neurology 1999;53(2):409-10. [PUBMED: 10430437]
35. Brinkmeier H, Wollinsky KH, Hulser PJ, Seewald MJ, Mehrkens H, Kornhuber HH, et al.The acute paralysis in Guillain-Barré syndrome is related to a Na+ channel blocking factor in the cerebrospinal fluid. Pflugers Archiv: European Journal of Physiology 1992;421:552-7. [PUBMED: 1331974]
36. Bussman JB, Garssen MP, van Doorn PA, Stam HJ. Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Journal of Rehabilitation Medicine 2007;39(2):121-5. [PUBMED: 17351693]
37. Cummins TR, Renganathan M, Stys PK, Herzog RI, Scarfo K, Horn R, et al.The pentapeptide QYNAD does not block voltage-gated sodium channels. Neurology 2003;60(2):224-9. [PUBMED: 12552035]
38. D'Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E, Liberati A. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD000022.pub3]
39. Demir SO, Köseoğlu F. Factors associated with health-related quality of life in patients with severe Guillain-Barré syndrome. Disability and Rehabilitation 2008;30(8):593-9. [PUBMED: 17852306]
40. Feasby TE, Hartung HP. Drain the roots: a new treatment for Guillain-Barré syndrome?. Neurology 2001;57(5):753-4. [PUBMED: 11551999]
41. Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, et al.Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2009;151(4):229-40. [PUBMED: 19687490]
42. Hadden RDM, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al.Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Annals of Neurology 1998;44(5):780-8. [PUBMED: 9818934]
43. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2008.
44. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2(8093):750-3. [PUBMED: 80682]
45. Hughes RAC. Guillain-Barré Syndrome. Heidelberg: Springer-Verlag, 1990.
46. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005;366(9497):1653-66. [PUBMED: 16271648]
47. Hughes RA, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007;130(Pt 9):2245-57. [PUBMED: 17337484]
48. Hughes RAC, Swan AV, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD001446.pub3]
49. Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, et al.Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010;74(8):651-7. [PUBMED: 20177118]
50. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012;7:CD002063. [DOI: 10.1002/14651858.CD002063.pub5]
51. Hughes RA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012;8:CD001446. [DOI: 10.1002/14651858.CD001446.pub4]
52. Jaso R, Sierra M, Calleja J, Valero C, Pascual J. Guillain-Barre syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?. Journal of Neurology 2010;257(3):488-9. [PUBMED: 20229293]
53. Khiani V, Kelly T, Shibli A, Jensen D, Mohanty SR. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. World Journal of Gastroenterology 2008;14(2):318-21. [PUBMED: 18186575]
54. Linker RA, Lee DH, Demir S, Wiese S, Kruse N, Siglienti I, et al.Functional role of brain derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 2010;133(8):2248-63. [PUBMED: 20826436]
55. Ludolph A (Department of Neurology, University of Ulm). Email to Prof RAC Hughes dated 1st September 2010. Located at Cochrane Neuromuscular Disease Group Editorial Base.
56. Mahdi-Rogers M, Swan AV, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD003280.pub3]
57. Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) 2009;48(8):944-52. [PUBMED: 19494179]
58. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006263.pub2]
59. Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999;53(8):1648-54. [PUBMED: 10563607]
60. Otto F, Kieseier BC, Gortz P, Hartung HP, Siebler M. The pentapeptide QYNAD does not inhibit neuronal network activity. Canadian Journal of Neurological Sciences 2005;32(3):344-8. [PUBMED: 16225177]
61. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349(9047):225-30. [PUBMED: 9014908]
62. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012;7:CD001798.
63. Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S, et al.Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clinical Neurophysiology 2008;119(11):2507-12. [PUBMED: 18829381]
64. Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. Journal of Neurology, Neurosurgery and Psychiatry 1998;64(1):74-7. [PUBMED: 9436731]
65. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
66. Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al.Interferon in relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002002]
67. Roche Products Limited. Cellcept Summary of Product Characteristics last updated on the eMC: 27/10/2009. Electronic Medicines Compendium (eMC) YR:2010.
68. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, de Baets MH, et al.An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71(6):400-6. [MEDLINE: 18434638]
69. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis and Rheumatism 2006;54(5):1429-34. [PUBMED: 16645971]
70. Turatti M, Tamburin S, Idone D, Praitano ML, Zanette G. Guillain-Barré syndrome after short-course efalizumab treatment. Journal of Neurology 2010;257(8):1404-5.
71. van Koningsveld R, Schmitz PI, van der Meché FG, Visser LH, Meulstee J, van Doorn PA for the Dutch GBS study group. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 2004;363:192-6.
72. Victor F, Menon K, Latkowski JA, Fernandez-Obregon A, Strober BE, Victor F, et al.Efalizumab-associated Guillain-Barré syndrome. Archives of Dermatology 2008;144(10):1396-7. [PUBMED: 18936412]
73. Wollinsky KH, Hülser PJ, Brinkmeier H, Mehrkens H-H, Kornhuber HH, Rüdel R. Clinical experiences with CSF filtration in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multiple sclerosis [Klinische Erfahrungen mit der CSF-Filtration bei Guillain-Barré Syndrom, chronisch inflammatorischer demyelinisierender Polyneuropathie und multipler Sklerose]. Neuropsychiatrie 1995;9:95-9.
74. Yuki N, Hartung HP. Guillain-Barré syndrome. New England Journal of Medicine 2012;366(24):2294-304.
75. Zhang L, Arrington S, Keung YK. Guillain-Barré syndrome after transplantation. Leukaemia and Lymphoma 2008;49(2):291-7.
76. Hughes RAC, Pritchard J, Hadden RDM. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome. Cochrane Database of Systematic Reviews 2010, Issue 8. [DOI: 10.1002/14651858.CD008630]
77. Hughes RAC, Pritchard J, Hadden RDM. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD008630.pub2]